+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Autism - Pipeline Review, H1 2019

  • ID: 4767143
  • Drug Pipelines
  • 195 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4D Pharma PLC
  • APeT Holding BV
  • Epigen Biosciences Inc
  • GlaxoSmithKline Plc
  • Insys Therapeutics Inc
  • Omeros Corp
  • MORE
Autism - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2019, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

This latest pipeline guide Autism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8, 6, 1, 20, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4D Pharma PLC
  • APeT Holding BV
  • Epigen Biosciences Inc
  • GlaxoSmithKline Plc
  • Insys Therapeutics Inc
  • Omeros Corp
  • MORE
Introduction

Autism - Overview

Autism - Therapeutics Development

Autism - Therapeutics Assessment

Autism - Companies Involved in Therapeutics Development

Autism - Drug Profiles

Autism - Dormant Projects

Autism - Discontinued Products

Autism - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Autism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Autism - Pipeline by 4D Pharma PLC, H1 2019

Autism - Pipeline by AgeneBio Inc, H1 2019

Autism - Pipeline by AMO Pharma Ltd, H1 2019

Autism - Pipeline by APeT Holding BV, H1 2019

Autism - Pipeline by BioHealthonomics Inc, H1 2019

Autism - Pipeline by Blackthorn Therapeutics Inc, H1 2019

Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2019

Autism - Pipeline by Curemark LLC, H1 2019

Autism - Pipeline by Epigen Biosciences Inc, H1 2019

Autism - Pipeline by Evgen Pharma Plc, H1 2019

Autism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Autism - Pipeline by GlaxoSmithKline Plc, H1 2019

Autism - Pipeline by GW Pharmaceuticals Plc, H1 2019

Autism - Pipeline by Immuron Ltd, H1 2019

Autism - Pipeline by Insys Therapeutics Inc, H1 2019

Autism - Pipeline by Intra-Cellular Therapies Inc, H1 2019

Autism - Pipeline by Johnson & Johnson, H1 2019

Autism - Pipeline by Leading BioSciences Inc, H1 2019

Autism - Pipeline by Omeros Corp, H1 2019

Autism - Pipeline by OptiNose US Inc, H1 2019

Autism - Pipeline by Ovensa Inc, H1 2019

Autism - Pipeline by Panorama Research Inc, H1 2019

Autism - Pipeline by RespireRx Pharmaceuticals Inc, H1 2019

Autism - Pipeline by Reviva Pharmaceuticals Inc, H1 2019

List of Figures

Number of Products under Development for Autism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Pharma PLC
  • AgeneBio Inc
  • AMO Pharma Ltd
  • APeT Holding BV
  • BioHealthonomics Inc
  • Blackthorn Therapeutics Inc
  • BrainStorm Cell Therapeutics Inc
  • Curemark LLC
  • Epigen Biosciences Inc
  • Evgen Pharma Plc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Immuron Ltd
  • Insys Therapeutics Inc
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Leading BioSciences Inc
  • Omeros Corp
  • OptiNose US Inc
  • Ovensa Inc
  • Panorama Research Inc
  • RespireRx Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Sosei Heptares
  • Sumitomo Dainippon Pharma Co Ltd
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll